Bayer’s FDA approval of Sunharbo (asundexian) on November 9 was a genuine milestone in cardiovascular medicine. It has zero bearing on the price of gold. That is the first thing a precious metals investor should understand this morning, because the story consuming pharma desks this week is being mistaken, in some corners, for a macro event worth watching. It is not.
What’s Driving the Market
Gold is under real pressure, and the source is entirely elsewhere. Gold prices extended losses for a third consecutive day, falling below $4,000 to an intraday low near $3,968 on November 12, as hotter-than-expected October CPI data and hawkish Fed signals heightened expectations for a December rate hike, lifting the U.S. Dollar Index to its highest level since April 2025 and pushing the 10-year Treasury yield toward 5%.
The Labor Department reported that consumer prices rose 0.4% in October against a 0.3% consensus, with core CPI up 0.3% versus the 0.2% economists expected. That one-tenth of a point overshoot was enough to change the conversation at the Fed entirely. Gold was already under pressure before the CPI release, as investors weighed comments from Federal Reserve Governor Christopher Waller, who said a 50-basis-point hike in December should be considered if core inflation ran at 0.3% or higher.
Futures markets now price a December hike as the base case. Futures have recently shown roughly high-80s to around 90% odds of a quarter-point December hike, and Friday’s producer price index is the next test for both metals. A hot PPI reading Friday could push the half-point scenario from a footnote into a live debate, and that is the version that tests support levels well below $3,900.
The one counterweight worth acknowledging: there has been strong buying in the third quarter of gold by central banks, which has really kept the floor on gold despite the short-term fundamental news of the Fed and interest rates working against it. That floor matters. Without it, the selloff this week would look worse.
Central bank demand has repeatedly proven its weight as a structural floor beneath gold prices. The divergence between sovereign buyers accumulating gold and ETF flows chasing Bitcoin reveals which demand base actually holds when rate pressure mounts.
The Investment Opportunity
When rate-hike fear drives a selloff, the distinction between paper gold and physical demand becomes the analytical edge. The World Gold Council’s Q3 2026 Gold Demand Trends report showed gold ETFs absorbed 211 tonnes, lifting total holdings to a record 4,256 tonnes. ETF holders who bought into that record are now sitting on unrealized losses from a metal that peaked near $5,600 in January. How they behave at $3,968 matters more to near-term direction than any pharmaceutical approval.
Silver’s industrial bid adds a separate dimension. Silver spot was trading at $52.67 per ounce on November 11, up 2.19% on the day, staging a faster rebound than gold from Tuesday’s selloff. The gold/silver ratio compressing from above 78 back toward 76 tells you that industrial demand is absorbing some of the pressure that rate-hike fear is applying to monetary metals.
Silver’s relative strength against gold is not always a reliable signal of industrial resilience. An earlier episode showed silver giving back gains sharply as bond markets absorbed the fear trade that metals investors expected to capture.
Risks to Monitor
The asymmetry in the current moment is worth spelling out. If Friday’s PPI surprises to the upside, gold faces a quick retest of the $3,968 low and possibly a move toward $3,872. If PPI comes in soft, rate-hike expectations ease and the central bank bid reasserts itself fast. Neither outcome requires watching Bayer’s stock.
The Sunharbo story is real and significant within pharma. The Phase 3 OCEANIC-STROKE trial showed that adding asundexian to standard antiplatelet therapy reduced recurrent ischemic stroke by 26% compared with placebo, without a statistically significant increase in major bleeding. That is a meaningful clinical result, and some Wall Street analysts see blockbuster potential for asundexian. Bayer shareholders have legitimate reasons to care about all of that.
Precious metals investors do not.
Bottom Line
Gold is trading on one dominant variable right now: whether the Federal Reserve raises rates in December and by how much. October CPI landed hotter than expected, Waller has floated 50 basis points publicly as a conditional scenario, and the dollar is at a 19-month high. Friday’s PPI is the next pivot point. That is the story. Everything else this week, including a first-in-class blood thinner for Bayer, is background noise.